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Available online 6 May 2017Type 2 diabetes mellitus (T2DM) has been associated with an increased risk of fractures, despite normal to in-
creased bone mineral density (BMD). Insulin use is one of the factors linked to this increased fracture risk. How-
ever, direct negative effects of insulin on bone quality are not expected since insulin is thought to be anabolic to
bone. In this cross-sectional study the association between insulin use and volumetric BMD (vBMD), bonemicro-
architecture and bone strength of the distal radius, asmeasuredwith HR-pQCT,was examined. Data from 50 par-
ticipantswith T2DMof TheMaastricht Study (mean age 62±7.5 years, 44%women)was used. Participantswere
classified as insulin user (n=13) or non-insulin user (n=37) based on prescription data. Linear regression anal-
ysiswas used to estimate the association between current insulin use andHR-pQCT derived parameters. After ad-
justment for age, sex, bodymass index, glycated hemoglobin A1c and T2DMduration, insulin use was associated
with lower total vBMD (standardized beta (β):−0.56 (95% CI:−0.89 to −0.24)), trabecular vBMD (β:−0.58
(95% CI:−0.87 to −0.30)), trabecular thickness (β:−0.55 (95% CI:−0.87 to −0.23)), cortical thickness
(β:−0.41 (95% CI:−0.74 to −0.08)), log cortical pore volume (β:−0.43 (95% CI:−0.73 to −0.13)), bone stiff-
ness (β:−0.39 (95% CI:−0.62 to−0.17)) and failure load (β:−0.39 (95% CI:−0.60 to−0.17)) when compared
to the non-insulin users. Insulin use was not associated with cortical vBMD, trabecular number, trabecular sepa-
ration, cortical porosity and cortical pore diameter. This study indicates that insulin use is negatively associatedKeywords:
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157E.A.C. de Waard et al. / Bone 101 (2017) 156–161with bone density, bone micro-architectural and bone strength parameters. These findings may partly explain
the previously observed increased fracture risk in insulin users, although there may be residual confounding
by other factors related to disease severity in insulin users.
© 2017 Elsevier Inc. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic dis-
ease leading to complications such as neuropathy, retinopathy and ne-
phropathy [1]. More recently, T2DM has been associated with an
increased risk of fractures, despite a normal to increased bone mineral
density (BMD) [2,3]. The mechanisms leading to this increased fracture
risk are not completely elucidated, but both an increased falling fre-
quency and bone fragility are thought to contribute to the increased
fracture risk [4,5]. Bone fragility can be the result of various factors,
and in patients with T2DM, among others, unfavorable changes in
micro- and macro-architecture of the bone, accumulation of advanced
glycation end products (AGEs) in bone collagen and a low bone turn-
over have been reported [4,5].
The use of antihyperglycemic drugs may also contribute to the in-
creased fracture risk. Except for thiazolidinediones, oral
antihyperglycemic drugs are not associated with an increased fracture
risk [6,7] However, insulin has been associated with an increased frac-
ture risk [7]. Since previous studies showed that insulinmay be anabolic
to bone [8] it has been hypothesized that the increased fracture risk in
insulin users is not caused by the drug itself. It is rather due to an in-
creased falling frequency and to the long-termnegative effects of hyper-
glycemia on bone quality, as insulin is most often used in patients with
long disease duration.
The association between hyperinsulinemia and areal BMD (aBMD)
in nondiabetic participants, as measured with DXA, has been examined
in several studies that demonstrated a positive association between
hyperinsulinemia and aBMD [9–11]. However, only two small studies
have examined the association between insulin therapy and aBMD in
patients with T2DM. Both showed a positive correlation between insu-
lin dose and aBMD [12,13].
High resolution peripheral quantitative computed tomography (HR-
pQCT) is a relatively new technique which can be used to measure vol-
umetric BMD (vBMD), micro-architecture and bone strength [14,15].
The association between insulin use and bone parameters measured
by HR-pQCT has not been studied before [7]. Therefore, the aim of this
study was to examine the association between insulin use and vBMD,
bone micro-architecture and bone strength in participants with T2DM.
It is hypothesized that insulin use will be positively associated with
HR-pQCT derived parameters when compared to non-insulin use.
2. Materials and methods
2.1. Source population
Data from The Maastricht Study, an ongoing observational prospec-
tive population-based cohort study, was used in the present study. The
rationale and methodology have been described previously [16]. In
brief, the study focuses on the etiology, pathophysiology, complications
and comorbidities of T2DM and is characterized by an extensive pheno-
typing approach. Eligible participantswere all individuals aged between
40 and 75 years and living in the southern part of the Netherlands. Par-
ticipants were recruited throughmassmedia campaigns aswell as from
the municipal registries and the regional Diabetes Patient Registry via
mailings. Recruitment was stratified according to known T2DM status,
with an oversampling of individuals with T2DM, for reasons of
efficiency.
To determine glucose metabolism status, all participants, except
thosewho used insulin, underwent a standardized 2-h 75 g oral glucosetolerance test (OGTT) after an overnight fast. For safety reasons, partic-
ipants with a fasting glucose level N 11.0 mmol/l (N200.0 mg/dl), as de-
termined by a capillary blood glucose measurement, did not undergo
the OGTT. Fasting glucose level, 2-h plasma glucose level and informa-
tion about diabetes medication were used to determine glucosemetab-
olism status. Participants were classified as having T2DM when they
had a fasting plasma glucose level ≥ 7.0 mmol/l (≥126 mg/dl) or a two
hour plasma glucose level ≥ 11.1 mmol/l (≥200 mg/dl) as specified by
the World Health Organization guidelines [17] or if they used
antihyperglycemic drugs at baseline. Individuals without type 1 diabe-
tes who used antihyperglycemic drugs were classified as having
T2DM. Participants who were not classified as T2DM, but did use an
antihyperglycemic drug in the six months prior to the date of the HR-
pQCT scan (based on their pharmacy data) were also included.
The present study includes cross-sectional data from participants
with T2DM who completed the baseline survey between November
2010 and September 2013 and returned to the research center between
March 2015 and February 2016 for the HR-pQCT scan of the distal radi-
us. Dispensing records were collected at the pharmacy for all partici-
pants who gave written informed consent for the collection of their
drug dispensing history. Dispensing data was available from January
1st 1991 through the date of theHR-pQCT scan and contained the prod-
uct name, the anatomical therapeutical chemical (ATC) code [18], the
dispensed quantity, the dispensing date and the prescribed daily dose
[19]. When a participant had a prescription for insulin (ATC code
A10A) in the six months before the date of the HR-pQCT scan, the par-
ticipant was classified as current insulin user. All other T2DM partici-
pants were classified as non-insulin users. The mean time since first
prescription of insulin was calculated from the prescription data.
The study has been approved by the institutional medical ethical
committee (NL31329.068.10) and the Minister of Health, Welfare and
Sports of the Netherlands (Permit 131,088-105,234-PG). All partici-
pants gave written informed consent.
2.2. HR-pQCT imaging
The non-dominant radius was scanned on an HR-pQCT scanner
(Xtreme-CT; Scanco Medical AG, Brüttisellen, Switzerland) using the
standard in vivo protocol as described in literature [20,21]. If the patient
has previously sustained a distal radius fracture at the non-dominant
site, the dominant site was scanned. The forearmwas placed into a car-
bon fiber cast. An anteroposterior scout projection of the scan site was
acquired for positioning of the tomographic acquisition. A reference
line was placed on the radial joint surface. The scan volume spanned
9.02 mm in length and started 9.5 mm from the reference line in the
proximal direction. Images were reconstructed using an isotropic
voxelsize of 82 μm, resulting in 110 consecutive slices. Total scan time
was 2.8 min, with each acquisition resulting in an effective dose of ap-
proximately 3 μSv. All scans were graded with regard to motion, and
scanswith quality 4 or 5were repeated once [22]. Only scanswith qual-
ity 1 to 3 were used for subsequent image analysis [23].
2.3. Image analysis of HR-pQCT scans
All scans were evaluated using the standard patient evaluation pro-
tocol that was provided by the manufacturer and that has been de-
scribed previously in detail [24–26]. First, the periosteal contour was
automatically derived and manually modified when contours visually
deviated from the periosteal boundary [27]. The images were
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were calculated from the images: total vBMD, trabecular vBMD and cor-
tical vBMD. In the trabecular region, themicro-architectural parameters
trabecular number, trabecular thickness and trabecular separationwere
calculated. For the cortical region, cortical thickness was calculated. In
addition, extended analysis of the cortical compartmentwas performed
to obtain cortical pore volume, cortical porosity and mean cortical pore
diameter [28]. Cortical pore volume was calculated as the volume of all
voxels identified as intracortical pore space. Cortical porosity was calcu-
lated as the ratio of the cortical pore volume to the total volume of the
cortical compartment.
Micro-finite element analysis was performed by creating micro-fi-
nite element models directly from the segmented HR-pQCT images as
described previously [29,30]. In short, all voxels representing bone tis-
sue were converted into brick elements of the same size. A Youngmod-
ulus of 10GPa and a Possion ratio of 0.3were assigned to every element.
Compression stiffness and estimated failure load were determined by
applying a virtual “high-friction’ compression test in the axial direction
[29].
2.4. Covariates
All covariates were determined at the baseline visit between No-
vember 2010 and September 2013. Weight and height were measured
without shoes and wearing light clothing using a scale and stadiometer
to the nearest 0.5 kg or 0.1 cm (Seca, Hamburg, Germany). BMI was cal-
culated by dividing weight in kilogram by height in meters squared.
HbA1c level and creatinine level were determined as described else-
where [16]. Alcohol use, smoking status (never, former or current), a
history of a fracture at or above the age of 50 and T2DM duration
were recorded at the baseline visit [18]. Alcohol consumption was clas-
sified into three categories: non-consumers, low consumers (≤7 glasses
per week for women and ≤14 glasses per week for men), and high con-
sumers (N7 glasses per week for women and N14 glasses per week for
men).
For the current study, the time between the baseline visit and the
date of the HR-pQCT scan was added to the T2DM duration at baseline.
If T2DM duration was not available, it was estimated by the time be-
tween the first antihyperglycemic prescription and the date of the HR-
pQCT scan. Use of other antihyperglycemic drugs in the six months be-
fore the date of the HR-pQCT scan was determined by the prescription
data using ATC codes: metformin (ATC code A10BA02,
A10BD02,03,05,07,08,10,11,13-18), sulfonylurea derivate (ATC code
A10BB, A10BD01, A10BD02), dipeptidyl peptidase 4 inhibitor (ATC
code A10BH), thiazolidinedione (A10BG) or other blood glucose lower-
ing drugs (A10BX). Use of anti-osteoporotic drugs and use of systemic
corticosteroids in the six months before the date of the HR-pQCT scan
was determined by the prescription data using ATC codes: drugs affect-
ing bone structure and mineralization (M05B) and corticosteroids for
systemic use (H02).
2.5. Statistical analysis
General characteristics were compared between the insulin and
non-insulin users. The independent student's t-test or the Mann-Whit-
ney U test was used to test for significant differences of continuous nor-
mal or not-normal distributed variables and a chi-square test for
differences in categorical variables. Log-transformation was performed
if variables showed a skewed distribution. Multiple linear regression
analysis was used to estimate the association between current use of in-
sulin and HR-pQCT derived parameters as compared to the non-insulin
users, yielding standardized beta's (β) and 95% confidence intervals
(CIs). The same models were used for all regression analyses: model 1
was adjusted for age and sex, model 2 was additionally adjusted for
BMI, HbA1c and duration of diabetes. A p-value b 0.05 was consideredstatistically significant and analyses were conducted using SAS 9.4
(SAS Institute Inc., Cary, NC, USA).
3. Results
In total, data from 59 T2DM participants who had a HR-pQCT scan
and pharmacy dispensing data available was retrieved. Data of eight
participants were excluded due to extreme motion artifacts of the HR-
pQCT scan (grade 5 n=2, grade 4 n=6) and data from one participant
was excluded because of extreme outliers. From the 50 included partic-
ipants, 13 were classified as insulin user and 37 were classified as non-
insulin user.
The general characteristics and themeanHR-pQCT derived bone pa-
rameters of the non-insulin and insulin users are shown in Table 1. The
non-insulin users were slightly older, had a shorter time since first hy-
perglycemic prescription, a shorter duration of diabetes and lower
mean HbA1c levels. There was no significant difference in the number
of fractures at or above the age of 50 and the use of anti-osteoporotic
drugs between the groups. Volumetric bone mineral density was
lower in the insulin users when compared to the non-insulin users
(total vBMD −67.6 mgHA/cm3, p b 0.01; trabecular vBMD
−30.3 mgHA/cm3, p = 0.03; cortical vBMD −54.16 mgHA/cm3, p =
0.06). Except for trabecular thickness being significantly lower in the in-
sulin users (−0.01 mm, p b 0.01), there were no differences in the tra-
becular micro-architecture between the groups. The cortical micro-
architecture of the insulin users was unfavorable compared to the
non-insulin users (cortical thickness − 0.20 mm, p = 0.02; cortical
pore volume − 5.80 mm3, p = 0.03; cortical porosity −2.38%, p =
0.38; cortical pore diameter − 0.01 mm, p = 0.08). Bone strength was
also lower in the insulin users (bone stiffness −18.39 kN/mm, p =
0.04; failure load−815.41 N, p = 0.05) when compared to the non-in-
sulin users.
The association between insulin use and HR-pQCT derived bone pa-
rameters is shown in Table 2. After adjustment for age, sex, BMI, HbA1c
and diabetes duration (model 2), current insulin use was associated
with parameters of volumetric bonemineral density, bonemicro-archi-
tecture and bone strength (volumetric bone mineral density: lower
total vBMD (β −0.56 (95% CI −0.89–−0.24)), trabecular vBMD (β
−0.58 (95% CI −0.87–−0.30)); micro-architecture: trabecular thick-
ness (β −0.55 (95% CI −0.87–−0.23)), cortical thickness (β −0.41
(95% CI −0.74–−0.08)), cortical pore volume (β −0.43 (95% CI
−0.73–−0.13)); strength: bone stiffness (β −0.39 (95% CI −0.62–
−0.17)), failure load (β −0.39 (95% CI −0.60–−0.17)) as compared
to the non-insulin users. Current insulin use was not associated with
cortical vBMD, trabecular number, trabecular separation, cortical poros-
ity and cortical pore diameter.
4. Discussion
The present study examined the association between current insulin
use and HR-pQCT derived bone parameters in patients with T2DM. Lit-
erature on the association between insulin therapy and BMD in T2DM
patients is scarce and there are no studies available that examined the
effects of insulin therapy on bone micro-architecture or bone strength.
Only two small studies have examined the association between insulin
dose and BMD, and both found a positive association [12,13]. In contrast
to these studies as well as our own hypothesis, the present study shows
that current insulin usewas associated with lower total vBMD, trabecu-
lar vBMD, trabecular thickness, cortical thickness, cortical pore volume,
bone stiffness and failure load as compared to non-insulin users after
adjustment for potential confounders.
In previous studies it was reported that insulin use is associatedwith
an increased fracture risk in T2DMpatients [7]. Themechanisms leading
to this increased fracture risk are not completely understood, but a di-
rect negative effect of insulin use of bonewas thought to be unlikely be-
cause in-vitro studies showed that insulin is an anabolic bone agent [8].
Table 1
General characteristics of the study population.
Non-insulin users
(n = 37)
Insulin users
(n = 13) p-value
Age, years 62.9 (7.6) 60.4 (5.9) 0.50
Female 15 (40.5) 6 (46.2) 0.72
BMI, kg/m2 30.3 (5.0) 30.9 (5.4) 0.71
Smoking status
Current 6 (16.2) 0 (0)
Former 17 (45.9) 10 (76.9) 0.08
Never 13 (35.1) 2 (15.4)
Missing 1 (2.7) 1 (7.7)
Alcohol use
None 6 (16.2) 5 (38.4)
Low 20 (54.1) 4 (30.8) 0.19
High 10 (27.0) 3 (23.1)
Missing 1 (2.7) 1 (7.7)
Time since first antihyperglycemic
prescription, years
4.1 [5.0] 8.5 [8.3] b0.01
Time since first insulin
prescription, years
n/a 7.0 [4.7] n/a
Use of drugs six months prior to the
scan
Metformin 26 (70.3) 8 (61.5) 0.56
Sulfonylurea derivatives 6 (16.2) 0 (0) 0.12
Dipeptidyl peptidase 4 inhibitors 0 (0) 2 (15.4) b0.01
Thiazolidinediones 0 (0) 0 (0) n/a
Other antihyperglycemic drugs 0 (0) 0 (0) n/a
Systemic corticosteroids 2 (5.4) 1 (7.7) 0.77
Anti-osteoporotic drugs 1 (2.7) 1 (7.7) 0.43
History of a fracture ≥50 years of
age
5 (13.5) 0 (0) 0.16
Duration of diabetes, years 4.1 [3.2] 14.7 [6.0] b0.01
HbA1c, % 6.6 (0.7) 7.7 (0.8) b0.01
Creatinine, μmol/L 77.5 (19.6) 79.9 (17.4) 0.70
Quality grade of HR-pQCT scan
1 8 (21.1) 3 (23.1)
2 21 (55.3) 6 (46.2) 0.87
3 9 (23.7) 4 (30.8)
HR-pQCT derived bone parameters
Bone mineral density
Total vBMD, mgHA/cm3 326.2 (75.6) 258.6 (61.0) b0.01
Trabecular vBMD, mgHA/cm3 173.1 (44.2) 142.9 (32.8) 0.03
Cortical vBMD, mgHA/cm3 854.0 (82.9) 799.9 (95.5) 0.06
Bone micro-architecture
Trabecular number, mm−1 1.95 (0.37) 1.95 (0.35) 0.98
Trabecular thickness, mm 0.07 (0.01) 0.06 (0.01) b0.01
Trabecular separation, mm 0.47 (0.17) 0.47 (0.10) 0.99
Cortical thickness, mm 0.84 (0.26) 0.64 (0.24) 0.02
Cortical pore volume, mm3 19.10 (8.76) 13.30 (5.79) 0.03
Cortical porosity, % 3.36 (1.21) 2.98 (1.64) 0.38
Cortical pore diameter, mm 0.18 (0.02) 0.17 (0.02) 0.08
Bone strength
Bone stiffness, kN/mm 100.5 (27.7) 82.1 (23.3) 0.04
Failure load, N 4796.5 (1298.2) 3981.1
(1101.5)
0.05
Continues variables are presented as mean (SD) or median [IQR], categorical variables as
number of participants (%). P-values in bold are statistically significant. Abbreviations:
HbA1c, glycated hemoglobin A1c; HR-pQCT, high resolution peripheral quantitative com-
puted tomography; n/a, not applicable; vBMD, volumetric bone mineral density.
Table 2
The association between insulin use and HR-pQCT derived bone parameters.
Model 1 (β (95% CI)) Model 2 (β (95% CI))
Bone mineral density
Total vBMD, mgHA/cm3 −0.39 (−0.65–−0.13)⁎ −0.56 (−0.89–−0.24)⁎
Trabecular vBMD, mgHA/cm3 −0.29 (−0.55–−0.04)⁎ −0.58 (−0.87–−0.30)⁎
Cortical vBMD, mgHA/cm3 −0.30 (−0.56–−0.05)⁎ −0.28 (−0.61–0.05)
Bone micro-architecture
Trabecular number, mm−1 0.00 (−0.27–0.27) −0.28 (−0.59–0.02)
Trabecular thickness, mm −0.41 (−0.66–−0.16)⁎ −0.55 (−0.87–−0.23)⁎
Trabecular separation, mm 0.00 (−0.26–0.27) 0.23 (−0.09–0.55)
Cortical thickness, mm −0.34 (−0.60–−0.08)⁎ −0.41 (−0.74–−0.08)⁎
Cortical pore volume, mm3 −0.29 (−0.52–−0.05)⁎ −0.43 (−0.73–−0.13)⁎
Cortical porosity, % −0.08 (−0.32–0.17) −0.20 (−0.51–0.12)
Cortical pore diameter, mm −0.24 (−0.50–0.03) −0.26 (−0.61–0.08)
Bone strength
Bone stiffness, kN/mm −0.27 (−0.45–−0.08)⁎ −0.39 (−0.62–−0.17)⁎
Failure load, N −0.25 (−0.43–−0.07)⁎ −0.39 (−0.60–−0.17)⁎
The analysis included 50 participants; 37 non-insulin users (reference group), and 13 in-
sulin users. Model 1: adjusted for age and sex. Model 2: model 1 + BMI, glycated hemo-
globin A1c and duration of diabetes. Cortical pore volume is log transformed.
⁎ Statistically significant, p b 0.05. Abbreviations: vBMD, volumetric bone mineral
density.
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and disease duration as insulin is most often used by T2DM patients
with long disease duration. The observed increased fracture risk in insu-
lin users may therefore be due to factors associated with the disease it-
self. For example, complications of T2DMand risk factors for falling such
as diabetic neuropathy and retinopathy are more common in patients
with long disease duration, and one of the proposed mechanisms of
the increased fracture risk in insulin users was therefore an increased
falling frequency. Additionally, it may be hypothesized that insulin
users are generallymore insulin resistant thannon-insulin users. Insulin
resistancemay result in impaired insulin signaling in osteoblasts, which
leads to impaired bone micro-architecture due to deteriorated osteo-
blast proliferation, differentiation and survival [31]. Insulin resistance
may therefore be anothermechanism leading to the observed increasedfracture risk in insulin users. Alternatively, a study in patients with
T2DM showed beta-cell decay over time [32], which leads to a decrease
in the endogenous insulin production and contributes negatively to
bone quality. In our study, the diabetes duration of the insulin users
was longer than the non-insulin users (14.7 vs 4.1 year, respectively),
and hypoinsulinemia may thus be more prominently present in the in-
sulin users, while substitution with exogenous insulin may not
completely mimic the effects of endogenous insulin. Furthermore, the
cumulative effect of chronic hyperglycemia will be larger in insulin
users than in non-insulin users. Long-term hyperglycemia may have
several negative effects on bone architecture, such as an increased for-
mation and accumulation of AGE's, which result in impaired bone colla-
gen quality and thereby decreased bone strength [33]. Elevated blood
glucose levels also lead to hypercalcuria [34], which may influence
bone mineralization. Finally, insulin users may be sarcopenic more
often than non-insulin users [35]. As muscle strength influences bone
strength, this may be anothermechanism resulting in an increased frac-
ture risk.
Although the results in this study are adjusted for HbA1c and disease
duration, which were used as proxies for effect of the disease itself,
there may still be residual confounding by other factors related to dis-
ease severity. Further information regarding disease severity such as
the presence of micro- and macrovascular complications will be very
useful to take into account, but for this study we did not have this infor-
mation. Additionally, we had no HR-pQCT data of participants with an
impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). In-
clusion of a group with IFG or IGT could help to test some of the above
mentioned hypotheses about the mechanism whereby insulin use is
negatively associated with HR-pQCT derived bone parameters.
Previous studies showed that T2DM is a low bone turnover condi-
tion, as both markers of bone formation and bone resorption are
lower in patients with T2DM than in healthy subjects [36,37]. It may
be hypothesized that changes in bonemicro-architecture may bemedi-
ated by changes in bone turnover markers, i.e. unfavorable vBMD, bone
micro-architecture and bone strength such as observed in our study are
accompanied by or preceded by an increase in bone resorption markers
while the bone formation markers are stable or decreased. Although no
literature is available on the effect of exogenous insulin substitution on
bone turnover markers, a study by Basu et al. found no alterations in
bone turnover markers during physiological changes in insulin levels
[38]. Additionally, higher levels of serum insulin were associated with
increased levels of the bone turnover markers [39], decreased levels of
bone resportion markers, and increased vBMD of the subtrochanteric
160 E.A.C. de Waard et al. / Bone 101 (2017) 156–161femur on low-resolution CT [40]. Unfortunately, no data on bone turn-
over markers was available in our study either. Future studies examin-
ing the association between insulin use and HR-pQCT derived bone
parameters should also measure bone turnover markers to verify this
hypothesis. Furthermore, DXA scans of the participants were not avail-
able. Due to the small number of participants wewere not able to adjust
for potential confounders such as use of glucocorticoids, a history of a
fracture at or above the age of 50, a parental history of hip fracture, vas-
cular complications of diabetes andmenopausal status.Within the non-
insulin user group there were some users of glucocorticoids, and use of
them has been associated with increased fracture risk [42] and this
might have confounded the investigated association. Finally, we used
an automatic instead of a semi-automatic algorithm to calculate cortical
bone parameters. It has been argued that on top of a trabecular and cor-
tical region, a transitional zone (the region between the trabecular and
cortical region) should be identified [43,44]. In this manuscript, the
endocortical contour was not manually adjusted to prevent intra-oper-
ator variability, and this may have resulted in over- or underestimation
of the cortical bone parameters.
This study has some limitations. First, this study has a cross-sectional
design and because of this design we can only speculate about the
mechanisms whereby insulin use is associated with impaired bone
quality. Second, because special clearance for radiological examinations
within The Maastricht Study by the Dutch Ministry of Health was re-
quired, HR-pQCT measurements started later during the course of the
study. Therefore, HR-pQCT data were available for a relatively small
number of participants resulting in reduced power of the study which
may have led to over- or underestimation of the associations [41]. The
present results should therefore be interpreted with caution. HR-pQCT
scans of the distal tibia were only recently allowed within the Maas-
tricht Study and therefore these scans were not available in our study
population. Since the distal tibia is a weight bearing bone, in contrast
to the distal radius, the association between insulin use and HR-pQCT
derived bone parameters at the distal tibia may be different and is sub-
ject for future analyses. Additionally, no information on vitamin D and
parathyroid hormone levels were available for the study population
and therefore patients with secondary osteoporosis may have been
included.
In conclusion, in this cross-sectional study we found that insulin use
was negatively associatedwith bonemineral density, bonemicro-archi-
tectural and bone strength parameters at the distal radius measured
with HR-pQCT in T2DMpatients. Therefore, the previously observed in-
creased fracture risk in insulin users might be partly due to bone fragil-
ity, although theremay be residual confounding by other factors related
to disease severity in insulin users. Replication of these findings in larg-
er, preferably longitudinal studies is needed.
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